Dr. Alan Goldhamer is one of the world’s top experts on fasting, and the Founder and Director of TrueNorth Health Center, where over 25,000 people have reversed chronic illnesses through medically supervised, water-only fasting. He is also the author of books such as, ‘Can Fasting Save Your Life?’ and ‘The Pleasure Trap’. Is fasting more powerful than any diet pill?! Dr Alan Goldhamer reveals how this simple practice burns belly fat, boosts energy, clears brain fog…and may even cure depression! He explains: ...

Core Insights - Anavex Life Sciences Corp. announced significant findings regarding its drug blarcamesine for early Alzheimer's disease, demonstrating up to 84.6 weeks (19.5 months) of 'time saved' through early treatment initiation [3][4][5] Group 1: Clinical Trial Results - The ATTENTION-AD Phase IIb/III trial showed that patients treated with blarcamesine continued to accrue cognitive and functional benefits over a period of up to 192 weeks [3] - In the intent-to-treat population, significant differences were observed in cognitive function (ADAS-Cog13) and daily living activities (ADCS-ADL) between early-start and late-start treatment groups at Week 192 [3] - The GWAS-identified population ABCLEAR24 showed even greater improvements in cognition (ADAS-Cog13: LS mean difference −5.43, P = 0.0035) and function (ADCS-ADL: LS mean difference +9.50, P < 0.0001) [3] Group 2: Mechanism of Action - Blarcamesine is confirmed to restore impaired autophagy by activating SIGMAR1, acting upstream of amyloid and tau pathologies [5][6] - The drug's mechanism was established through both in vitro and in vivo studies, demonstrating enhanced autophagic flux and increased proteostasis capacity [6][7] Group 3: Safety Profile - Blarcamesine exhibited a favorable safety profile with no treatment-related deaths reported during the trials [4][5] - Common treatment-emergent adverse events included transient dizziness, mostly mild to moderate in severity [8] Group 4: Future Implications - The findings suggest that earlier initiation of treatment with blarcamesine may significantly impact disease progression and provide sustained benefits for patients with early Alzheimer's disease [5][9] - The company emphasizes the importance of a long-term therapeutic strategy for chronic diseases like Alzheimer's, with blarcamesine's convenient once-daily oral dosing potentially enhancing patient adherence [9]